Exelixis, Inc. (EXEL)
Exelixis, Inc. (EXEL) is a healthcare company (biotechnology) based in the United States. The share price is $68.05, up 1.42% on the day, which values the company at $16.6B. Price as of 17 Nov 2026, 17:22 UTC, from Yahoo Finance.
Key facts
- Share price
- $68.05+1.42% today
- Market value
- $16.6B
- P/E ratio
- 20.4×last 12 months
- Forward P/E
- 15.9×
- Funk Score
- 78/100
- Against its own history
- Well above its usual priceusual price $48.62
- 200-week average
- $33.97100% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Exelixis, Inc. in more detail
EXEL trades at 20.4× its last twelve months' earnings, 15.9× next year's expected earnings, 6.7× sales. Measured against its own history, the price is 40% above what its usual multiples would imply ($48.62) — well above its usual price. It sits 100% above its 200-week average of $33.97.
Over the last five fiscal years Exelixis, Inc. has compounded revenue 19.1% a year, earnings per share 22.2% a year, free cash flow 10.4% a year. Its Funk Score is 78 out of 100 (financial strength 9.6, profitability 9.8, growth 8.4, value 3.6, each out of 10).
In its favour: Strong Piotroski score; Share count keeps falling.
5 of the superinvestors tracked here hold EXEL, including Andrew Spokes (4.5% of the portfolio), Jim Simons (1938–2024) (1.0% of the portfolio), Josef Lakonishok (0.9% of the portfolio).
Superinvestors holding EXEL
5 of the investors tracked here report a position in their latest 13F filing.
- Andrew Spokes Farallon Capital Management4.47% of portfolio · $858.3M · added · Q3 2026
- Jim Simons (1938–2024) Renaissance Technologies1.02% of portfolio · $747.2M · trimmed · Q3 2026
- Josef Lakonishok LSV Asset Management0.85% of portfolio · $460.8M · trimmed · Q3 2026
- Cliff Asness AQR Capital Management0.21% of portfolio · $598.6M · trimmed · Q2 2026
- David Shaw (founder) D. E. Shaw & Co.0.19% of portfolio · $302.1M · added · Q2 2026
Health Care companies of similar size
- Guardant HealthGH
- Alnylam PharmaceuticalsALNY
- Zimmer Biomet HoldingsZBH
- Medpace HoldingsMEDP
- RevvityRVTY
- Charles River Laboratories InternationalCRL
- Neurocrine BiosciencesNBIX
- Ascendis PharmaASND
- ICONICLR
- Jazz PharmaceuticalsJAZZ
- SolventumSOLV
- BridgeBio PharmaBBIO
Side by side:EXEL vs CRL (Exelixis, Inc. vs Charles River Laboratories International)EXEL vs NBIX (Exelixis, Inc. vs Neurocrine Biosciences)EXEL vs RVTY (Exelixis, Inc. vs Revvity)EXEL vs ASND (Exelixis, Inc. vs Ascendis Pharma)EXEL vs MEDP (Exelixis, Inc. vs Medpace Holdings)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Exelixis, Inc. (EXEL): questions and answers
What is EXEL's P/E ratio?
Exelixis, Inc. trades at 20.4× its last twelve months' earnings and 15.9× next year's expected earnings. At its fiscal year-ends over the past 10 years the P/E ranged from 8.2× to 62.0×, with a median of 22.2×.
What is EXEL's PEG ratio?
Exelixis, Inc.'s PEG ratio is 2.56 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Exelixis, Inc.'s market cap?
Exelixis, Inc. is valued at $16.6B at a share price of $68.05.
Is EXEL overvalued or undervalued?
Against its own history, EXEL is well above its usual price: the price is 40% above the $48.62 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is EXEL above its 200-week moving average?
Yes. EXEL is 100.3% above its 200-week average of $33.97. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Exelixis, Inc. growing?
Over the last five fiscal years Exelixis, Inc.'s revenue grew 19.1% a year and its earnings per share 22.2% a year; over ten years revenue grew 51.2% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Exelixis, Inc. (EXEL) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/EXEL
Underlying data: Yahoo Finance; company filings with the SEC.